Avicanna Inc. announced that it will be entering into an import and distribution agreement with Astral Health Ltd. to supply its cannabis-based medicines to patients in the U.K. under the MHRA “specials” program. Under the agreement, both Avicanna and Astral will work together to achieve key strategic milestones in the U.K. in terms of market activation, market access, and safety.
Avicanna has announced its agreement to be a supplier for the British cannabis market.
Avicanna Inc. (TSX: AVCN), a biopharmaceutical company focused on the development, manufacture, and commercialization of organic and sustainable herbal cannabinoid-based products, just announced that the Company has entered into an import and distribution agreement with Astral Health Ltd., the operating subsidiary of LYPHE Group Ltd, to supply its cannabis-based medicines (“CBMPs”) to patients in the U.K. under the MHRA “specials” program.
Avicanna and Astral work together in the British cannabis market
Under the agreement, Avicanna will supply Astral with CBMPs and both Avicanna and Astral will work together to achieve key strategic milestones in the British cannabis market in terms of activation, access, and safety.
The parties will also work together to develop medical education programs focusing on product safety, dosage recommendations, and efficacy. The agreement will enable Avicanna to generate sales from the growing British cannabis market while giving patients better access to the medicine they need.
The CBMPs are expected to be manufactured in Colombia using the research-based formulations developed by Avicanna and cannabis extracts from Santa Marta Golden Hemp S.A.S., a subsidiary of Avicanna.
They will be manufactured at the facilities of Avicanna’s exclusive Colombian manufacturer, Altea Farmaceutica S.A., using Good Manufacturing Practices (GMP).
Astral lays the groundwork for the market
Astral is a European focused importer and distributor of medical cannabis and is part of the LYPHE Group.
LYPHE has developed a patient access ecosystem that has laid the groundwork for the British cannabis market and has enabled the company to become a market leader in the country’s fast-growing sector.
Avicanna is a Canadian company focused on the development, manufacture, and marketing of plant-based cannabinoid products in its two main business areas of cultivation and research and development.
Avicanna’s two wholly-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia, are the basis for Avicanna’s cultivation activities.
Research and development continues to be conducted in Canada
These two companies are licensed to grow and process cannabis for the production of cannabis extracts and purified cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC).
Avicanna’s research and development is primarily conducted from Canada at its headquarters at the Johnson & Johnson Innovation Centre, JLABS in Toronto.
Avicanna’s own scientific team develops products and is working with researchers from the Leslie Dan Faculty of Pharmacy at the University of Toronto to develop and improve the company’s products for distribution to the British cannabis market.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in FinanzNachrichten, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.